New England Capital Financial Advisors’s Heron Therapeutics HRTX Stock Holding History

New England Capital Financial Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$203	Hold	475	–	–	﹤0.01%	415
2026 Q1	$381	Hold	475	–	–	﹤0.01%	397
2025 Q4	$618	Hold	475	–	–	﹤0.01%	385
2025 Q3	$599	Hold	475	–	–	﹤0.01%	384
2025 Q2	$984	Hold	475	–	–	﹤0.01%	365
2025 Q1	$1.04K	Hold	475	–	–	﹤0.01%	336
2024 Q4	$727	Hold	475	–	–	﹤0.01%	365
2024 Q3	$946	Hold	475	–	–	﹤0.01%	345
2024 Q2	$1.66K	Hold	475	–	–	﹤0.01%	324
2024 Q1	$1.32K	Hold	475	–	–	﹤0.01%	329
2023 Q4	$808	Hold	475	–	–	﹤0.01%	350
2023 Q3	$490	Hold	475	–	–	﹤0.01%	359
2023 Q2	$551	Hold	475	–	–	﹤0.01%	353
2023 Q1	$718	Hold	475	–	–	﹤0.01%	388
2022 Q4	$1.4K	Buy	+475	New	+$1.53K	﹤0.01%	364

Other funds holding HRTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

CPC

Congress Park Capital Saratoga Springs, New York $370M AUM 26.01% 1-Year Est. Return

Richmond Brothers Jackson, Michigan $192M AUM 23.02% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

New England Capital Financial Advisors's HRTX Position: Q2 2026 in Review

New England Capital Financial Advisors held its Heron Therapeutics (HRTX) position steady in Q2 2026 at 475 shares worth $203. The position accounts for ﹤0.01% of the portfolio, ranked #415.

New England Capital Financial Advisors first reported a position in HRTX in Q4 2022 and has held it in 15 quarters since. The position peaked at $1.66K in Q2 2024. 96 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

New England Capital Financial Advisors held 475 shares of Heron Therapeutics worth $203 as of Q2 2026.
New England Capital Financial Advisors left its Heron Therapeutics share count unchanged in Q2 2026.
Heron Therapeutics made up ﹤0.01% of New England Capital Financial Advisors's portfolio in Q2 2026, its #415 holding.
New England Capital Financial Advisors first reported a position in Heron Therapeutics in Q4 2022 and has held it in 15 quarters since.
New England Capital Financial Advisors's Heron Therapeutics position peaked at $1.66K in Q2 2024.
96 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on New England Capital Financial Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.